The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: A trial of the University of Chicago phase II consortium

Investigational New Drugs

Volumn 28, Issue 6, 2010, Pages 854-858

  Nimeiri, Halla S ^d   Singh, Deepti A ^a   Kasza, Kristen ^b   Taber, David A ^c   Ansari, Rafat H ^c   Vokes, Everett E ^a   Kindler, Hedy L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Northern Indiana Cancer Research Consortium   (United States)

^d NONE

Author keywords

Epothilone; Hepatobiliary cancers

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; IXABEPILONE; NIZATIDINE; ORAL ANTIDIABETIC AGENT; RANITIDINE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIABETES MELLITUS; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; HEPATOBILIARY SYSTEM CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; HYPOGLYCEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROTUBULE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; EPOTHILONES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; UNIVERSITIES; YOUNG ADULT;

EID: 78549295200     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9297-6     Document Type: Article

References (21)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. RA Smith V Cokkinides HJ Eyre 2005 American cancer society guidelines for the early detection of cancer, 2005 CA Cancer J Clin 55 31 44 10.3322/canjclin.55.1.31 15661685 quiz 55-36
3. T Patel 2002 Worldwide trends in mortality from biliary tract malignancies BMC Cancer 2 10 10.1186/1471-2407-2-10 11991810 (Pubitemid 38851311)
4. HB El-Serag JA Davila NJ Petersen KA McGlynn 2003 The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 817 823 14623619
5. PC de Groen GJ Gores NF LaRusso, et al. 1999 Biliary tract cancers N Engl J Med 341 1368 1378 10.1056/NEJM199910283411807 10536130 (Pubitemid 29503577)
6. M Huang G Liu 1999 The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line Cancer Lett 135 97 105 1:CAS:528:DyaK1MXht1Smtrc%3D 10.1016/S0304-3835(98)00280-8 10077227
7. A Kato M Miyazaki S Ambiru, et al. 2001 Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection J Surg Oncol 78 110 115 1:STN:280: DC%2BD3Mrjt1Gqtg%3D%3D 10.1002/jso.1129 11579388 (Pubitemid 32906122)
8. MT Kuo JY Zhao LD Teeter, et al. 1992 Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice Cell Growth Differ 3 531 540 1:CAS:528:DyaK3sXmt1ejtr4%3D 1356418
9. RG Simonetti A Liberati C Angiolini L Pagliaro 1997 Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials Ann Oncol 8 117 136 1:STN:280:DyaK2s3kslGqsA%3D%3D 10.1023/A:1008285123736 9093719 (Pubitemid 27112878)
10. T Andre C Tournigand O Rosmorduc, et al. 2004 Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 1339 1343 1:STN:280:DC%2BD2cvhsVektg%3D%3D 10.1093/annonc/mdh351 15319238 (Pubitemid 39295020)
11. J Harder B Riecken O Kummer, et al. 2006 Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer Br J Cancer 95 848 852 1:CAS:528:DC%2BD28XhtVans7jK 10.1038/sj.bjc.6603334 16969352 (Pubitemid 44498100)
12. S Goodin MP Kane EH Rubin 2004 Epothilones: mechanism of action and biologic activity J Clin Oncol 22 2015 2025 1:CAS:528:DC%2BD2cXptlCks7w%3D 10.1200/JCO.2004.12.001 15143095 (Pubitemid 41095195)
13. FY Lee R Borzilleri CR Fairchild, et al. 2001 BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 1429 1437 1:CAS:528: DC%2BD3MXktlels7Y%3D 11350914
14. SM Gadgeel A Wozniak RR Boinpally, et al. 2005 Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design Clin Cancer Res 11 6233 6239 1:CAS:528:DC%2BD2MXpslansL4%3D 10.1158/1078-0432. CCR-05-0127 16144926 (Pubitemid 41262953)
15. SH Zhuang M Agrawal M Edgerly, et al. 2005 A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days Cancer 103 1932 1938 1:CAS:528:DC%2BD2MXktFGntrw%3D 10.1002/cncr.20977 15800893 (Pubitemid 40563267)
16. J Abraham M Agrawal S Bakke, et al. 2003 Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days J Clin Oncol 21 1866 1873 1:CAS:528:DC%2BD2cXpsVWqt7o%3D 10.1200/JCO.2003.03.063 12721265 (Pubitemid 46638601)
17. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
18. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 1:STN:280:DyaL1M7ps1SjsQ%3D%3D 10.1016/0197-2456(89) 90015-9 2702835 (Pubitemid 19099520)
19. R Brookmeyer J Crowley 1982 A confidence interval for the median survival time Biometrics 38 29 41 10.2307/2530286
20. A Venook R Poon YK Kang 2007 Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 25 15055 ASCO Annual Meeting Proceedings
21. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514